PharmAthene Reports Year-End 2016 Financial and Operational Results PR Newswire ANNAPOLIS, Md., March 14, 2017 ANNAPOLIS, Md., March 14, 2017 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a...
PRINCETON JUNCTION, N.J., July 18, 2014 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (NYSE:MG), is pleased to announce that it has signed a multi-year teaming agreement with Altran North America...
Interview with Chairman & Chief Executive Philippe Salle Altran (Paris:ALT), the global leader in innovation and high-tech engineering consulting, held it's Investor & Analyst Day...
MONTVALE, N.J., July 24 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) announces that the reverse stock split of its common stock and name change will be in effect from Wednesday, July 25...
** Name Change to Synvista Therapeutics, Inc. and Reverse Stock Split to be Effective July 25 ** MONTVALE, N.J., July 20 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) announced that at its...
COMPANY PRESENTATION TO BE WEBCAST LIVE MONTVALE, N.J., July 18 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) announces that its Annual Meeting of Stockholders will be held on Friday, July...
MONTVALE, N.J., July 16 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) announces the appointment of Jacob Victor, Ph.D. as Executive Director, Product Development, Clinical Diagnostics...
Proof of Concept Study for Pharmacogenomic Indication MONTVALE, N.J., June 28 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) announced today that it has dosed its first patient in a 60-patient...
MONTVALE, N.J., May 11 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) announced today that Noah Berkwitz, MD, PhD, President and Chief Executive Officer, will deliver a corporate presentation...
MONTVALE, N.J., April 19 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) In compliance with the AMEX Company Guide Rule 610(b) requiring a public announcement of the receipt of an audit report...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FU |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FU |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FU |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FU |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FU |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FU |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FU |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales